Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: 180 Life Sciences Corp. ATNF

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody discussed the company’s continued status to remain on track with clinical development … Continue reading

Posted in 180 Life Sciences Corp. ATNF | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Collects 2b Disease Trial Data; Receives NASDAQ Notice Regarding Annual Report

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its phase 2b Dupuytren’s disease trial, … Continue reading

Posted in 180 Life Sciences Corp. ATNF, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Colleague Receives 2021 International Dupuytren Award

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that Dr. Lynn Williams, PhD, has received the International Dupuytren Award … Continue reading

Posted in 180 Life Sciences Corp. ATNF | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Releases Stockholder Letter

180 Life Sciences Corp. (NASDAQ: ATNF) CEO James Woody, MD, PhD, has issued a letter to ATNF stockholders. In the letter he provides an overview of the company’s activities and accomplishments since his last stockholder letter, which was released in … Continue reading

Posted in 180 Life Sciences Corp. ATNF, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Inaugural Emerging Growth Virtual Conference

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at the Inaugural Emerging Growth Virtual Conference, hosted … Continue reading

Posted in 180 Life Sciences Corp. ATNF, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on Private Placement with Gross Proceeds of $11.7M

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced the closing of its previously announced private placement. The private placement … Continue reading

Posted in 180 Life Sciences Corp. ATNF, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at the Biotech Showcase(TM) Digital 2021 Conference

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at … Continue reading

Posted in 180 Life Sciences Corp. ATNF, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at LD Micro Main Event

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will participate … Continue reading

Posted in 180 Life Sciences Corp. ATNF, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Ring Nasdaq Opening Bell

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that, in celebration of … Continue reading

Posted in 180 Life Sciences Corp. ATNF | Leave a comment